4.5 hours: the new time window for tissue plasminogen activator in stroke.
Davis
Stephen M
SM
Division of Neurosciences, Department of Neurology, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia. stephen.davis@mh.org.au
Donnan
Geoffrey A
GA
D000208:Acute Disease; D002543:Cerebral Hemorrhage / Q000150:complications; D017326:Clinical Trials, Phase III as Topic; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D017408:Guidelines as Topic; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology; D015912:Thrombolytic Therapy / Q000592:standards* / Q000706:statistics & numerical data; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator